What is TSRL?
TSRL, Inc. is a preclinical contract research organization (CRO) headquartered in Ann Arbor, Michigan. The company specializes in supporting pharmaceutical, biotech, and academic entities in the advancement of early-stage drug candidates. TSRL offers a comprehensive suite of integrated services, including bioanalysis, formulation development, toxicology studies, and strategic consulting, all meticulously designed to align with specific therapeutic objectives and project timelines. By leveraging scientific acumen and practical industry experience, TSRL aims to mitigate risks and generate high-quality, actionable data essential for effective drug development. Their advanced facility is equipped with extensive wet lab capabilities to accommodate diverse testing and research requirements.
How much funding has TSRL raised?
TSRL has raised a total of $335K across 2 funding rounds:
Debt
$150K
Debt
$185K
Debt (2020): $150K with participation from PPP
Debt (2021): $185K led by PPP
Key Investors in TSRL
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for TSRL?
With its recent large-scale late-stage funding, TSRL is strategically positioned to accelerate its growth and expand its service offerings. This capital injection will likely fuel enhancements in its research infrastructure, bolster its scientific team, and potentially broaden its client base. The company's focus on providing integrated CRO services for early drug development suggests a trajectory aimed at becoming a key partner for emerging and established life science companies seeking to de-risk and expedite their pipelines. Future developments may include strategic partnerships or acquisitions to further solidify its market position and technological capabilities.
See full TSRL company page
